欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2025, Vol. 30 ›› Issue (11): 1479-1490.doi: 10.12092/j.issn.1009-2501.2025.11.004

• 食欲素及其受体阻断剂治疗失眠障碍研究进展 • 上一篇    下一篇

失眠障碍的发生机制和药物干预策略

寇梁,夏昀,王涛   

  1. 华中科技大学同济医学院附属协和医院神经内科,武汉  430022,湖北
  • 出版日期:2025-11-26 发布日期:2025-12-04
  • 通讯作者: 王涛,华中科技大学同济医学院附属协和医院主任医师,二级教授,博士生导师,中国睡眠研究会常务理事,中国康复医学会睡眠障碍康复专业委员会主任委员,湖北省睡眠研究会理事长,中华医学会神经病学分会帕金森病及运动障碍学组委员,中国老年保健协会脑保健专业委员会副主任委员,中国老年医学学会神经医学分会副会长,中华神经科杂志等杂志编委,J Pathology、J Alzheimer Disease、Science Advances等SCI期刊评审专家,主持国家自然科学基金项目7项,发表SCI论文80余篇,作为主要完成人获湖北省科技进步二等奖3项。 E-mail:wangtaowh@hust.edu.cn
  • 基金资助:
    国家自然科学基金项目(82171424;82471456)

Mechanisms and pharmacological intervention strategies of insomnia disorder

KOU Liang, XIA Yun, WANG Tao   

  1. Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China
  • Online:2025-11-26 Published:2025-12-04

摘要: 睡眠是维持人类身心健康的基石。失眠障碍作为全球范围内最普遍的睡眠障碍,显著提升了罹患心脑血管疾病、精神疾病及神经退行性疾病的风险。研究表明,过度觉醒可能是失眠障碍病理生理机制中的“最终共同通路”。当前,失眠障碍的一线干预手段主要是认知行为治疗和药物治疗。然而,常用的苯二氮?类和非苯二氮?类镇静催眠药存在耐受性、依赖性及次日残留效应等局限性,制约了其临床应用。近年来,食欲素受体拮抗剂的问世为治疗带了新突破。该药通过阻断食欲素受体,靶向抑制过度觉醒,促进自然睡眠,副作用较少且无成瘾性,为失眠障碍的药物治疗开辟了新路径。本综述将围绕失眠障碍的病理生理机制与药物治疗策略展开论述,以期为临床治疗提供参考。

关键词: 睡眠, 过度觉醒, 苯二氮卓类, 镇静催眠药, 食欲素系统, 食欲素双受体拮抗剂, 抗抑郁药, 认知行为

Abstract: Sleep is crucial for human physical and mental health. However, insomnia is one of the most prevalent sleep disorders worldwide and significantly increases the risk of cardiovascular and cerebrovascular diseases, mental illnesses, and neurodegenerative disorders. Researches suggested that hyperarousal may be the final common pathway in the pathophysiology of insomnia. Current intervention strategies for insomnia mainly include cognitive-behavioral therapy and pharmacological treatment. Commonly used medications primarily consist of benzodiazepines and non-benzodiazepine sedative-hypnotics. However, limitations such as tolerance, dependence, and next-day residual effects make these drugs unable to meet clinical treatment needs. Orexin receptor antagonists inhibit the hyperarousal state by blocking orexin receptors, prolonging both rapid eye movement (REM) and non-REM sleep, and promoting natural sleep. With fewer side effects and no addictive potential, they offer new hope for the treatment of insomnia. This article aims to summarize the pathophysiological mechanisms of insomnia and current pharmacological treatment strategies, providing a reference for clinical insomnia management.

Key words: sleep, hyperarousal, benzodiazepines, sedative-hypnotics, orexin system, dual orexin receptor antagonists, antidepressants, cognitive-behavioral therapy

中图分类号: